Net Income (Loss) Attributable to Parent in USD of Y-mAbs Therapeutics, Inc. from Q1 2017 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Y-mAbs Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q2 2025.
  • Y-mAbs Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$3.24M, a 65% increase year-over-year.
  • Y-mAbs Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$22.2M, a 9.71% increase year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$29.7M, a 38.5% decline from 2023.
  • Y-mAbs Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.4M, a 77.6% increase from 2022.
  • Y-mAbs Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$95.6M, a 72.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Y-mAbs Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 -$22.2M -$3.24M +$6.01M +65% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-08
Q1 2025 -$28.2M -$5.2M +$1.43M +21.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-08-08
Q4 2024 -$29.7M -$6.79M -$5.8M -587% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-04
Q3 2024 -$23.9M -$7M +$749K +9.67% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 -$24.6M -$9.25M -$2.95M -46.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-08
Q1 2024 -$21.7M -$6.63M -$239K -3.74% Jan 1, 2024 Mar 31, 2024 10-Q 2025-08-08
Q4 2023 -$21.4M -$988K -$2.15M -185% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-04
Q3 2023 -$19.3M -$7.75M +$19.8M +71.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 -$39.1M -$6.3M +$34.8M +84.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-08
Q1 2023 -$73.9M -$6.39M +$21.7M +77.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-08
Q4 2022 -$95.6M $1.16M +$38.1M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$134M -$27.5M +$1.33M +4.62% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$135M -$41.1M -$18.2M -79.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$117M -$28.1M -$61.5M -184% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$55.3M -$36.9M -$17M -85.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$38.3M -$28.9M +$3.97M +12.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$42.3M -$22.9M +$17.5M +43.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$59.7M $33.4M +$59.6M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$119M -$19.9M +$3.2M +13.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$123M -$32.8M -$8.91M -37.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$114M -$40.4M -$22.4M -124% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$91.3M -$26.2M -$10.2M -64.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$81M -$23.1M -$9.08M -64.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$72M -$23.9M -$12.5M -109% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$59.5M -$18M -$7.73M -75% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$51.7M -$15.9M -$8.45M -113% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$43.3M -$14.1M -$4.81M -52% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$38.5M -$11.4M -$7.6M -199% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$30.9M -$10.3M -$7.11M -223% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$23.8M -$7.48M -$4.59M -159% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$19.2M -$9.25M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-22
Q3 2017 -$3.83M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-22
Q2 2017 -$3.19M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-22
Q1 2017 -$2.89M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-22

Y-mAbs Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$29.7M -$8.24M -38.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-04
2023 -$21.4M +$74.1M +77.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-04
2022 -$95.6M -$40.3M -72.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-29
2021 -$55.3M +$64.1M +53.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 -$119M -$38.3M -47.3% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-01
2019 -$81M -$37.8M -87.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$43.3M -$24.1M -126% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
2017 -$19.2M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.